Abstract
Angiogenesis is the process of capillary sprouting from pre-existing vessels and it plays a critical role in the carcinogenic process of lung adenocarcinoma (LUAD). However, the association of angiogenesis regulators with the prognosis and progression of LUAD needs to be further elucidated. In this study, we adopted differential expression analysis, Cox proportional hazards (PH) regression analysis and experimental validation to identify angiogenesis regulators correlated with a poor prognosis, immune infiltration and cancer progression in LUAD. These results showed that the diagnostic and prognostic models based on COL5A2 and EPHB2 served as independent biomarkers with superior predictive ability. The patients in the high-risk group exhibited a worse prognosis in the TCGA cohort (P < 0.001, HR = 1.72, 95% CI 1.28-2.30), GSE310210 cohort (P = 0.005, HR = 2.87, 95% CI 1.46-5.61), and GSE31019 cohort (P = 0.01, HR = 2.14, 95% CI 1.19-3.86) than patients in the low-risk group. The high prognostic risk patients had a higher TMB (P < 0.001); higher fractions of M0 macrophages, neutrophils, NK cells resting, and T cells CD4 memory activated (P < 0.05); and higher expression of immune checkpoints PD-1, PDL-1, PDL-2, and B7H3 (P < 0.001). Patients in the high-risk group were more sensitive to chemotherapeutic drugs and molecular targeted drugs such as cisplatin, doxorubicin, gefitinib, and bosutinib (P < 0.0001). In addition, inhibition of COL5A2 and EPHB2 effectively suppressed the proliferation and migration of LUAD cells. The current study identified angiogenesis regulators as potential biomarkers and therapeutic targets for LUAD and may help to further optimize cancer therapy.
Introduction
Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer and remains a leading cause of cancer-related mortality globally. Despite advancements in immunotherapy and targeted treatments, the five-year survival rate for LUAD patients remains disappointingly low, largely due to late-stage diagnosis. A hallmark of cancer progression is angiogenesis—the formation of new blood vessels that supply tumors with essential nutrients and oxygen. While the general importance of angiogenesis is established, the specific regulators driving LUAD progression and their relationship with the tumor microenvironment require deeper investigation. This study aimed to identify key angiogenic genes that could serve as both prognostic biomarkers and therapeutic targets.
Identification of Angiogenic Regulators
Using a comprehensive bioinformatics pipeline, researchers analyzed 154 angiogenesis-related genes using data from The Cancer Genome Atlas (TCGA). Differential expression analysis and Cox proportional hazards regression were employed to identify genes with the most significant prognostic impact.
As shown in the initial screening, numerous genes were differentially expressed between normal and tumor tissues. Functional enrichment analysis (Gene Ontology and PPI networks) confirmed that these genes are primarily involved in biological processes such as angiogenesis, endothelium development, and extracellular structure organization, reinforcing their relevance to tumor vascularization.
The Two-Gene Prognostic Signature: COL5A2 and EPHB2
From the initial pool of candidates, the study narrowed down the focus to two critical genes: COL5A2 (a collagen chain) and EPHB2 (an ephrin receptor). A Prognostic Index (PI) was developed based on these two genes, allowing patients to be categorized into high-risk and low-risk groups.
Across multiple independent cohorts (TCGA and GEO), patients in the high-risk group consistently showed significantly worse survival outcomes. Interestingly, high-risk patients also exhibited a higher Tumor Mutation Burden (TMB) and increased expression of key immune checkpoints, including PD-1, PD-L1, and B7H3. This suggests that while these tumors are more aggressive, they may be particularly susceptible to immune checkpoint inhibitors. Furthermore, drug sensitivity analysis indicated that high-risk patients might respond more favorably to standard chemotherapies like cisplatin and targeted therapies like gefitinib.
Experimental Validation of Oncogenic Effects
To transition from bioinformatics correlations to functional evidence, the researchers performed in vitro experiments using LUAD cell lines (A549 and H1299). By using siRNA to silence the expression of COL5A2 and EPHB2, they directly observed the impact on cancer cell behavior.
The experimental results were definitive: inhibition of either COL5A2 or EPHB2 significantly reduced cell proliferation, as measured by CCK-8 and EdU assays. Moreover, Transwell migration assays demonstrated a dramatic decrease in the invasive capacity of the cancer cells following knockdown. These findings confirm that COL5A2 and EPHB2 are not merely markers of disease but active drivers of LUAD progression and metastasis.
Conclusion and Future Directions
This study successfully identified a robust two-gene signature—COL5A2 and EPHB2—that serves as a powerful diagnostic and prognostic tool for LUAD. These genes are linked to increased angiogenesis, higher immune infiltration, and specific therapeutic vulnerabilities. While these results are promising, future work involving prospective clinical trials and in vivo animal models is necessary to fully translate these findings into clinical practice and to map the precise signaling pathways involved.
Summary updated